Targeting macrophage-myofibroblast transition with Caulis spatholobi to attenuate renal interstitial fibrosis: integrated UHPLC-Q-Exactive Orbitrap-MS, network pharmacology, and experimental validation

TL;DR

This study explores how Caulis Spatholobi extract may treat kidney fibrosis by targeting macrophage transformation and reducing tissue damage in rats.

Contribution

The study integrates advanced analytical methods and experimental validation to reveal the anti-fibrotic mechanisms of Caulis Spatholobi.

Findings

AECS reduced renal tissue damage and dysfunction in RIF rat models.

AECS downregulated fibrosis markers α-SMA and fibronectin in RIF rats.

AECS treatment reduced MMT cell populations, especially CD206+α-SMA+ cells, indicating a role for M2 macrophages in RIF.

Abstract

Caulis Spatholobi (CS), a traditional Chinese medicine, is recognized for its abilities to reduce fibrinogen levels, promote proteolysis, and improve conditions such as diabetic nephropathy. However, the potential of aqueous extract of CS (AECS) as an effective treatment for renal interstitial fibrosis (RIF) is yet to be established.

The AECS was qualitative analyzed by UHPLC-Q-Exactive Orbitrap-MS. Potential targets of AECS were predicted, and RIF disease targets were collated from databases. A Venn diagram was generated using the EVenn platform, and drug-active ingredient-target network diagrams were constructed with Cytoscape 3.10.1 software. The PPI network was generated through the STRING database, and GO and KEGG enrichment analyses were executed via the DAVID platform. Molecular docking predictions of active ingredients binding with core targets were conducted using the CB-Dock2 platform. Finally, the anti-RIF effect of AECS was evaluated in an adenine-induced rat model.

A total of 64 chemical constituents were identified in the AECS. 97 common targets for treating RIF were identified through mining multiple databases. These key targets, particularly AKT1, EGFR and IL6, mediated biological functions such as protein phosphorylation and regulated several signaling pathways, including PI3K/Akt. Molecular docking studies demonstrated that ingredients like licochalcone A exhibited strong binding affinity with hub genes such as AKT1, EGFR and IL6. In an RIF rat model, treatment groups showed reduced renal tissue damage. Furthermore, treatment with AECS significantly ameliorated renal dysfunction in RIF rats, along with a downregulation of RIF markers α-SMA and fibronectin. Compared to the AECSL group, the LST and AECSH groups (300mg/kg/d) exhibited more significant therapeutic effects. Ultimately, RIF model rats showed increased expression of pan-macrophage marker CD68 and M2-specific marker CD206, along with α-SMA co-expression, indicating differentiation into MMT cells displaying CD68+α-SMA+ or CD206+α-SMA+ immunophenotypes. LST and AECS treatments significantly reduced MMT cell populations, with CD206+α-SMA+ cells being more abundant than CD68+α-SMA+ cells, emphasizing the key role of M2 macrophages in MMT-driven RIF. MMT-derived M1-like cells secreted IL-6 while M2-like cells produced IL-10, AECS downregulated both cytokines.

Our study is expected to provide the pharmacological mechanisms by which CS may be a promising anti-RIF drug for future clinical trials.

A scientific workflow diagram showing three main sections: UHPLC-Q-Exactive Orbitrap-MS featuring images of Caulis Spatholobi and related spectra; Network Pharmacology including Venn diagrams, network interactions, and molecular docking results; Experimental Verification presenting rodent model results, tissue samples in different groups, and various histological analyses. Each section connects sequentially, illustrating the research process.

Figures